or Try an Advanced Search...

    Resistant Prostate Cancer Stocks List

    Symbol Grade Name % Change
    EXEL A Exelixis, Inc. 2.77
    CRDF B Cardiff Oncology, Inc. 2.72
    AMGN C Amgen Inc. -0.29
    View As Page of Charts
    Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Major
    Related Stock Lists: Prostate Cancer Biotechnology Cancer Drugs Medicine Metastatic Castration Resistant Prostate Cancer Acute Myeloid Leukemia Adenosine Advanced Solid Tumors Antineoplastic Drugs Blood Cells Bone Bone Disease Cancer Care Cancer Treatment Chemotherapy Clinic Clinical Medicine Colorectal Cancer Cyclopropanes

    Related ETFs - A few ETFs which own one or more of the above listed Resistant Prostate Cancer stocks.

    Symbol Grade Name Weight
    BBH D Market Vectors Biotech ETF 16.72
    BIS C ProShares UltraShort Nasdaq Biotechnology 8.87
    IBBQ D Invesco Nasdaq Biotechnology ETF 8.68
    PBE C PowerShares Dynamic Biotech & Genome 8.28
    HRTS D Tema Cardiovascular and Metabolic ETF 7.87
    View all Resistant Prostate Cancer ETFs...
    Compare ETFs
    Compare BIS to HRTS Compare BIS to IBBQ Compare IBBQ to HRTS

        Resistant Prostate Cancer Stocks Recent News

        Date Stock Title
        Nov 1 EXEL Exelixis, Inc. Just Recorded A 18% EPS Beat: Here's What Analysts Are Forecasting Next
        Nov 1 AMGN Amgen Third Quarter 2024 Earnings: EPS Beats Expectations
        Oct 31 AMGN Amgen earns higher revenues in Q3 2024, puts rare diseases in the spotlight
        Oct 31 AMGN Q3 2024 Amgen Inc Earnings Call
        Oct 31 AMGN Amgen 'Laser-Focused' On Its Weight-Loss Shot As New Rival Pfizer Follows, Says CFO
        Oct 31 EXEL Exelixis: Cabometyx Drives Revenue While Zanzalintinib Emerges As Future Growth Engine
        Oct 31 AMGN Amgen Q3 Earnings Beat, Sales In Line, Obesity Candidate in Focus
        Oct 31 EXEL Exelixis price target raised to $36 from $33 at Piper Sandler
        Oct 31 AMGN Amgen Inc (AMGN) Q3 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic Pipeline ...
        Oct 31 AMGN Amgen Inc. (AMGN) Q3 2024 Earnings Call Transcript
        Oct 31 AMGN Amgen Inc. 2024 Q3 - Results - Earnings Call Presentation
        Oct 31 AMGN Amgen (AMGN) Q3 2024 Earnings Call Transcript
        Oct 30 AMGN Amgen updates 2024 guidance with revenue and EPS ranges including consensus
        Oct 30 AMGN Compared to Estimates, Amgen (AMGN) Q3 Earnings: A Look at Key Metrics
        Oct 30 AMGN Amgen (AMGN) Beats Q3 Earnings Estimates
        Oct 30 CRDF Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC
        Oct 30 AMGN Amgen in charts: Prolia, XGEVA sales gain, while Enbrel continues to wind down in Q3
        Oct 30 AMGN Amgen: Q3 Earnings Snapshot
        Oct 30 AMGN Amgen Non-GAAP EPS of $5.58 beats by $0.47, revenue of $8.5B in-line
        Oct 30 AMGN Amgen posts higher profit, obesity data on track for late this year
        Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Major
        Related Stock Lists: Prostate Cancer Biotechnology Cancer Drugs Medicine Metastatic Castration Resistant Prostate Cancer Acute Myeloid Leukemia Adenosine Advanced Solid Tumors Antineoplastic Drugs Blood Cells Bone Bone Disease Cancer Care Cancer Treatment Chemotherapy Clinic Clinical Medicine Colorectal Cancer Cyclopropanes
        Resistant Prostate Cancer

        Resistant prostate cancer is a type of prostate cancer that has become resistant to hormone therapy, which is the most common form of treatment for prostate cancer. This type of cancer is more difficult to treat and may require more aggressive treatments such as chemotherapy or radiation therapy.

        Browse All Tags